Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 676 publications

Adverse Events of Immune Checkpoint Inhibitors in Cancer Patients with Comorbid Diabetes: A Real-World Pharmacovigilance Analysis of the FDA Adverse Event Reporting System Database (2011-2025).

Adverse Events of Immune Checkpoint Inhibitors in Cancer Patients with Comorbid Diabetes: A Real-World Pharmacovigilance Analysis of the FDA Adverse Event Reporting System Database (2011-2025).

Journal: Cancer control : journal of the Moffitt Cancer Center
Published: September 19, 2025

Agranulocytosis Following Durvalumab Plus Tremelimumab Therapy for Hepatocellular Carcinoma: A Case Report.

Agranulocytosis Following Durvalumab Plus Tremelimumab Therapy for Hepatocellular Carcinoma: A Case Report.

Journal: Internal medicine (Tokyo, Japan)
Published: September 10, 2025

The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.

The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.

Journal: Internal medicine (Tokyo, Japan)
Published: September 03, 2025

Efficacy and Safety of Hypofractionated Radiation Therapy Combined With Immunotherapy for Hepatocellular Carcinoma With Vp4 Portal Vein Tumor Thrombosis.

Efficacy and Safety of Hypofractionated Radiation Therapy Combined With Immunotherapy for Hepatocellular Carcinoma With Vp4 Portal Vein Tumor Thrombosis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: August 25, 2025

Tremelimumab for the treatment of hepatocellular carcinoma.

Tremelimumab for the treatment of hepatocellular carcinoma.

Journal: Expert opinion on biological therapy
Published: August 20, 2025

Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Biomarker in Advanced Hepatocellular Carcinoma Treated with First-Line Immunotherapy.

Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Biomarker in Advanced Hepatocellular Carcinoma Treated with First-Line Immunotherapy.

Journal: Journal of gastrointestinal cancer
Published: August 12, 2025

Remarkable response to durvalumab and tremelimumab in a patient with hepatocellular carcinoma: a case report.

Remarkable response to durvalumab and tremelimumab in a patient with hepatocellular carcinoma: a case report.

Journal: Clinical journal of gastroenterology
Published: July 29, 2025

Veno-arterial extracorporeal membrane oxygenation support for cardiogenic shock secondary to immune checkpoint inhibitors.

Veno-arterial extracorporeal membrane oxygenation support for cardiogenic shock secondary to immune checkpoint inhibitors.

Journal: Perfusion
Published: July 29, 2025

The use of durvalumab and tremelimumab after atezolizumab and bevacizumab in patients with hepatocellular carcinoma: case report and literature review.

The use of durvalumab and tremelimumab after atezolizumab and bevacizumab in patients with hepatocellular carcinoma: case report and literature review.

Journal: Immunotherapy
Published: July 28, 2025

Contemporary Clinical Utilization of Radioembolization with Immune Checkpoint Inhibitors as First-Line Treatment in HCC: Real-World Report on Safety and Outcomes.

Contemporary Clinical Utilization of Radioembolization with Immune Checkpoint Inhibitors as First-Line Treatment in HCC: Real-World Report on Safety and Outcomes.

Journal: Cancers
Published: July 22, 2025

Immunotherapy versus lenvatinib in hepatocellular carcinoma: the need for granular data and prospective validation.

Immunotherapy versus lenvatinib in hepatocellular carcinoma: the need for granular data and prospective validation.

Journal: Journal for immunotherapy of cancer
Published: July 19, 2025

Neoadjuvant Immunotherapy in Bladder Cancer: Ushering in a New Era of Treatment-A Systematic Review of Current Evidence.

Neoadjuvant Immunotherapy in Bladder Cancer: Ushering in a New Era of Treatment-A Systematic Review of Current Evidence.

Journal: European urology open science
Published: July 19, 2025
Showing 1-12 of 676

Last Updated: 10/31/2025